The Ischemic Stroke Genetics Study (ISGS) Protocol

被引：41

作者：

James F Meschia

Thomas G Brott

Robert D Brown

Richard JP Crook

Michael Frankel

John Hardy

José G Merino

Stephen S Rich

Scott Silliman

Bradford Burke Worrall

机构：

[1] Department of Neurology, Mayo Clinic, Jacksonville, FL

[2] Department of Neuroscience, Mayo Clinic, Jacksonville, FL

[3] Emory University School of Medicine, Atlanta, GA

[4] National Institute of Aging, Bethesda, MD

[5] University of Florida, Shands Hospital, Jacksonville, FL

[6] Dept. of Public Health Sci./Neurol., Wake Forest University Sch. of Med., Winston-Salem, NC

[7] University of Virginia Health System, Charlottesville, VA

来源：

BMC Neurology | / 3卷 / 1期

关键词：

Ischemic Stroke; Acute Ischemic Stroke; Candidate Gene Association Study; Abstracted Medical Record; Ischemic Stroke Risk;

D O I：

10.1186/1471-2377-3-4

中图分类号：

学科分类号：

摘要：

Background: The molecular basis for the genetic risk of ischemic stroke is likely to be multigenic and influenced by environmental factors. Several small case-control studies have suggested associations between ischemic stroke and polymorphisms of genes that code for coagulation cascade proteins and platelet receptors. Our aim is to investigate potential associations between hemostatic gene polymorphisms and ischemic stroke, with particular emphasis on detailed characterization of the phenotype. Methods/Design: The Ischemic Stroke Genetic Study is a prospective, multicenter genetic association study in adults with recent first-ever ischemic stroke confirmed with computed tomography or magnetic resonance imaging. Patients are evaluated at academic medical centers in the United States and compared with sex- and age-matched controls. Stroke subtypes are determined by central blinded adjudication using standardized, validated mechanistic and syndromic classification systems. The panel of genes to be tested for polymorphisms includes β-fibrinogen and platelet glycoprotein Ia, Iba, and IIb/IIIa. Immortalized cell lines are created to allow for time- and cost-efficient testing of additional candidate genes in the future. Discussion: The study is designed to minimize survival bias and to allow for exploring associations between specific polymorphisms and individual subtypes of ischemic stroke. The data set will also permit the study of genetic determinants of stroke outcome. Having cell lines will permit testing of future candidate risk factor genes. © 2003 Meschia et al; licensee BioMed Central Ltd.

引用

共 73 条

[1]

Endarterectomy for asymptomatic carotid artery stenosis, JAMA, 273, pp. 1421-1428, (1995)

[2]

Gambaro G., Anglani F., D'Angelo A., Association studies of genetic polymorphisms and complex disease, Lancet, 355, pp. 308-311, (2000)

[3]

del Zoppo G.J., Higashida R.T., Furlan A.J., Pessin M.S., Rowley H.A., Gent M., PROACT: A phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke, Stroke, 29, pp. 4-11, (1998)

[4]

Furlan A., Higashida R., Wechsler L., Gent M., Rowley H., Kase C., Pessin M., Ahya A., Callahan F., Clark W.M., Et al., Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism, JAMA, 282, pp. 2003-2011, (1999)

[5]

Lewandowski C.A., Frankel M., Tomsick T.A., Broderick J., Frey J., Clark W., Starkman S., Grotta J., Spilker J., Khoury J., Et al., Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial, Stroke, 30, pp. 2598-2605, (1999)

[6]

Tissue plasminogen activator for acute ischemic stroke, N. Engl. J. Med., 333, pp. 1581-1587, (1995)

[7]

Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients, BMJ, 308, pp. 81-106, (1994)

[8]

Hart R.G., Benavente O., McBride R., Pearce L.A., Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: A meta-analysis, Ann. Intern. Med., 131, pp. 492-501, (1999)

[9]

Zuber M., Toulon P., Marnet L., Mas J.L., Factor V Leiden mutation in cerebral venous thrombosis, Stroke, 27, pp. 1721-1723, (1996)

[10]

Kessler C., Spitzer C., Stauske D., Mende S., Stadlmuller J., Walther R., Retlig R., The apolipoprotein E and beta-fibrinogen G/A-455 gene polymorphisms are associated with ischemic stroke involving large-vessel disease, Arterioscler. Thromb. Vasc. Biol., 17, pp. 2880-2884, (1997)

← 1 2 3 4 5 6 7 8 →